Phase 1b Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide, and Dexamethasone in Newly Diagnosed, Transplant-ineligible Multiple Myeloma Patients

Documenti analoghi

• DP111 | POSITRON EMISSION TOMOGRAPHY WITH COMPUTED TOMOGRAPHY AND MINIMAL RESIDUAL DISEASE FOR EFFICACY ASSESSMENT IN TRANSPLANT-INELIGIBLE NEWLY DIAGNOSED MYELOMA PATIENTS: IMROZ ANALYSIS
  di: E. Zamagni, et al.
  Pubblicazione: (2025-09-01)
• Isatuximab plus bortezomib, lenalidomide, and dexamethasone for transplant-ineligible newly diagnosed multiple myeloma patients: a frailty subgroup analysis of the IMROZ trial
  di: Salomon Manier, et al.
  Pubblicazione: (2025-03-01)
• <i>Erratum</i> to: “Isatuximab plus bortezomib, lenalidomide, and dexamethasone for transplant-ineligible newly diagnosed multiple myeloma patients: a frailty subgroup analysis of the IMROZ trial”
  di: Salomon Manier, et al.
  Pubblicazione: (2026-07-01)
• Bir ismin etnografisi: İmroz’dan Gökçeada’ya
  di: Hasan Münüsoğlu
  Pubblicazione: (2021-06-01)
• Phase 1b Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide, and Dexamethasone in Newly Diagnosed, Transplant-ineligible Multiple Myeloma Patients
  di: Enrique M. Ocio, et al.
  Pubblicazione: (2023-02-01)